Branden Manns






Health Econ

Contact information


Office : HRIC 2AC58

Research and teaching

Research areas

  • Nephrology
  • Economics
  • Health Policy


Dr. Braden Manns is a Professor in Health Economics, a Kidney Specialist at the University of Calgary and the Associate Chief Medical Officer for the Alberta Health Services’ Strategic Clinical Networks.  He has experience in pharmaceutical priority setting, including a term as Chair of Canadian Expert Drug Advisory Committee, and patient oriented research. His research expertise is in applied health economics. Current research interests include examining the implications of patient-borne costs on care and outcomes in chronic disease, examining the cost effectiveness of health care policies for managing patients with chronic disease, and assessing the implications of different ways to pay physicians. 


Braden J. Manns, Helen Lee, Christopher James Doig, David Johnson, Cam Donaldson.  An Economic Evaluation of Activated Protein C Treatment in Severe Sepsis. New England Journal of Medicine, 2002; 347: 993-1000 
Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas, N, Quinn R, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, and Manns BJ.  The Impact of Frequent Nocturnal Hemodialysis and Conventional Hemodialysis on Left Ventricular Mass and Quality of Life.  JAMA, 2007; 298(11): 1291-99
Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.  JAMA. 2009 Oct 7;302(13):1437-43
Manns B, Hemmelgarn B, Lillie E, Dip SC, Cyr A, Gladish M, Large C, Silverman H, Toth B, Wolfs W, Laupacis A. Setting Research Priorities for Patients on or Nearing Dialysis. Clin J Am Soc Nephrol. 2014 May 15
Campbell DJ, Tonelli M, Hemmelgarn B, Mitchell C, Tsuyuki R, Ivers N, Campbell T, Pannu R, Verkerke E, Klarenbach S, King-Shier K, Faris P, Exner D, Chaubey V, Manns B; Interdisciplinary Chronic Disease Collaboration.  Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2×2 factorial randomized trial.  Implement Sci. 2016 Sep 26;11(1):131.


2017 Kidney Foundation of Canada Gold Medal For Research Excellence
2016 University of Calgary Peak Scholar Nominee
2016 Alberta Venture Magazine’s 50 Most Influential People